Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Validation of Novel Mycobacterium tuberculosis Isoniazid Resistance Mutations Not Detectable by Common Molecular Tests.

Kandler JL, Mercante AD, Dalton TL, Ezewudo MN, Cowan LS, Burns SP, Metchock B; Global PETTS Investigators, Cegielski P, Posey JE.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00974-18. doi: 10.1128/AAC.00974-18. Print 2018 Oct.

2.

Initial Public Health Laboratory Response After Hurricane Maria - Puerto Rico, 2017.

Concepción-Acevedo J, Patel A, Luna-Pinto C, Peña RG, Cuevas Ruiz RI, Arbolay HR, Toro M, Deseda C, De Jesus VR, Ribot E, Gonzalez JQ, Rao G, De Leon Salazar A, Ansbro M, White BB, Hardy MC, Georgi JC, Stinnett R, Mercante AM, Lowe D, Martin H, Starks A, Metchock B, Johnston S, Dalton T, Joglar O, Stafford C, Youngblood M, Klein K, Lindstrom S, Berman L, Galloway R, Schafer IJ, Walke H, Stoddard R, Connelly R, McCaffery E, Rowlinson MC, Soroka S, Tranquillo DT, Gaynor A, Mangal C, Wroblewski K, Muehlenbachs A, Salerno RM, Lozier M, Sunshine B, Shapiro C, Rose D, Funk R, Pillai SK, O'Neill E.

MMWR Morb Mortal Wkly Rep. 2018 Mar 23;67(11):333-336. doi: 10.15585/mmwr.mm6711a5.

3.

Role of the Health Department in Tuberculosis Prevention and Control-Legal and Public Health Considerations.

Jeffries C, Lobue P, Chorba T, Metchock B, Kashef I.

Microbiol Spectr. 2017 Mar;5(2). doi: 10.1128/microbiolspec.TNMI7-0034-2016. Review.

PMID:
28256190
4.
5.

A Multilaboratory, Multicountry Study To Determine Bedaquiline MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing.

Kaniga K, Cirillo DM, Hoffner S, Ismail NA, Kaur D, Lounis N, Metchock B, Pfyffer GE, Venter A.

J Clin Microbiol. 2016 Dec;54(12):2956-2962. Epub 2016 Sep 21.

6.

Molecular and Growth-Based Drug Susceptibility Testing of Mycobacterium tuberculosis Complex for Ethambutol Resistance in the United States.

Yakrus MA, Driscoll J, McAlister A, Sikes D, Hartline D, Metchock B, Starks AM.

Tuberc Res Treat. 2016;2016:3404860. doi: 10.1155/2016/3404860. Epub 2016 Jun 8.

7.

Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings.

Luetkemeyer AF, Firnhaber C, Kendall MA, Wu X, Mazurek GH, Benator DA, Arduino R, Fernandez M, Guy E, Johnson P, Metchock B, Sattler F, Telzak E, Wang YF, Weiner M, Swindells S, Sanne IM, Havlir DV, Grinsztejn B, Alland D; AIDS Clinical Trials Group A5295 and Tuberculosis Trials Consortium Study 34 Teams.

Clin Infect Dis. 2016 May 1;62(9):1081-8. doi: 10.1093/cid/ciw035. Epub 2016 Feb 2.

8.

Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance.

Cegielski JP, Kurbatova E, van der Walt M, Brand J, Ershova J, Tupasi T, Caoili JC, Dalton T, Contreras C, Yagui M, Bayona J, Kvasnovsky C, Leimane V, Kuksa L, Chen MP, Via LE, Hwang SH, Wolfgang M, Volchenkov GV, Somova T, Smith SE, Akksilp S, Wattanaamornkiet W, Kim HJ, Kim CK, Kazennyy BY, Khorosheva T, Kliiman K, Viiklepp P, Jou R, Huang AS, Vasilyeva IA, Demikhova OV; Global PETTS Investigators, Lancaster J, Odendaal R, Diem L, Perez TC, Gler T, Tan K, Bonilla C, Jave O, Asencios L, Yale G, Suarez C, Walker AT, Norvaisha I, Skenders G, Sture I, Riekstina V, Cirule A, Sigman E, Cho SN, Cai Y, Eum S, Lee J, Park S, Jeon D, Shamputa IC, Metchock B, Kuznetsova T, Akksilp R, Sitti W, Inyapong J, Kiryanova EV, Degtyareva I, Nemtsova ES, Levina K, Danilovits M, Kummik T, Lei YC, Huang WL, Erokhin VV, Chernousova LN, Andreevskaya SN, Larionova EE, Smirnova TG.

Clin Infect Dis. 2016 Feb 15;62(4):418-430. doi: 10.1093/cid/civ910. Epub 2015 Oct 27.

9.

Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis.

Willby M, Sikes RD, Malik S, Metchock B, Posey JE.

Antimicrob Agents Chemother. 2015 Sep;59(9):5427-34. doi: 10.1128/AAC.00662-15. Epub 2015 Jun 22.

10.

Evaluation of a u.s. Public health laboratory service for the molecular detection of drug resistant tuberculosis.

Yakrus MA, Metchock B, Starks AM.

Tuberc Res Treat. 2015;2015:701786. doi: 10.1155/2015/701786. Epub 2015 Feb 22.

11.

DNA sequencing for confirmation of rifampin resistance detected by Cepheid Xpert MTB/RIF assay.

McAlister AJ, Driscoll J, Metchock B.

J Clin Microbiol. 2015 May;53(5):1752-3. doi: 10.1128/JCM.03433-14. Epub 2015 Mar 4.

12.

Concordance between molecular and phenotypic testing of Mycobacterium tuberculosis complex isolates for resistance to rifampin and isoniazid in the United States.

Yakrus MA, Driscoll J, Lentz AJ, Sikes D, Hartline D, Metchock B, Starks AM.

J Clin Microbiol. 2014 Jun;52(6):1932-7. doi: 10.1128/JCM.00417-14. Epub 2014 Mar 19.

13.

Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study.

Dalton T, Cegielski P, Akksilp S, Asencios L, Campos Caoili J, Cho SN, Erokhin VV, Ershova J, Gler MT, Kazennyy BY, Kim HJ, Kliiman K, Kurbatova E, Kvasnovsky C, Leimane V, van der Walt M, Via LE, Volchenkov GV, Yagui MA, Kang H; Global PETTS Investigators, Akksilp R, Sitti W, Wattanaamornkiet W, Andreevskaya SN, Chernousova LN, Demikhova OV, Larionova EE, Smirnova TG, Vasilieva IA, Vorobyeva AV, Barry CE 3rd, Cai Y, Shamputa IC, Bayona J, Contreras C, Bonilla C, Jave O, Brand J, Lancaster J, Odendaal R, Chen MP, Diem L, Metchock B, Tan K, Taylor A, Wolfgang M, Cho E, Eum SY, Kwak HK, Lee J, Lee J, Min S, Degtyareva I, Nemtsova ES, Khorosheva T, Kyryanova EV, Egos G, Perez MT, Tupasi T, Hwang SH, Kim CK, Kim SY, Lee HJ, Kuksa L, Norvaisha I, Skenders G, Sture I, Kummik T, Kuznetsova T, Somova T, Levina K, Pariona G, Yale G, Suarez C, Valencia E, Viiklepp P.

Lancet. 2012 Oct 20;380(9851):1406-17. doi: 10.1016/S0140-6736(12)60734-X. Epub 2012 Aug 30. Erratum in: Lancet. 2012 Oct 20;380(9851):1386.

PMID:
22938757
14.

Multidrug-resistant tuberculosis drug susceptibility and molecular diagnostic testing.

Kalokhe AS, Shafiq M, Lee JC, Ray SM, Wang YF, Metchock B, Anderson AM, Nguyen ML.

Am J Med Sci. 2013 Feb;345(2):143-8. doi: 10.1097/MAJ.0b013e31825d32c6. Review.

15.

Rifampicin-resistant Mycobacterium tuberculosis: susceptibility to isoniazid and other anti-tuberculosis drugs.

Kurbatova EV, Cavanaugh JS, Shah NS, Wright A, Kim H, Metchock B, Van Deun A, Barrera L, Boulahbal F, Richter E, Martín-Casabona N, Arias F, Zemanova I, Drobniewski F, Santos Silva A, Coulter C, Lumb R, Cegielski JP.

Int J Tuberc Lung Dis. 2012;16(3):355-7. doi: 10.5588/ijtld.11.0542.

16.

Discordance in Mycobacterium tuberculosis rifampin susceptibility.

Kalokhe AS, Shafiq M, Lee JC, Metchock B, Posey JE, Ray SM, Anderson A, Wang YF, Nguyen ML.

Emerg Infect Dis. 2012 Mar;18(3):537-9. doi: 10.3201/eid1803.111357. No abstract available.

17.

Performance of tuberculosis drug susceptibility testing in U.S. laboratories from 1994 to 2008.

Angra PK, Taylor TH, Iademarco MF, Metchock B, Astles JR, Ridderhof JC.

J Clin Microbiol. 2012 Apr;50(4):1233-9. doi: 10.1128/JCM.06479-11. Epub 2012 Feb 1.

18.

Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa.

Mac Kenzie WR, Heilig CM, Bozeman L, Johnson JL, Muzanye G, Dunbar D, Jost KC Jr, Diem L, Metchock B, Eisenach K, Dorman S, Goldberg S.

PLoS One. 2011 Apr 11;6(4):e18358. doi: 10.1371/journal.pone.0018358.

19.

Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis.

Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchock B, Starks AM, Hooks DP, Cowan LS, Plikaytis BB, Posey JE.

Antimicrob Agents Chemother. 2011 May;55(5):2032-41. doi: 10.1128/AAC.01550-10. Epub 2011 Feb 7.

20.

Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis.

Zaunbrecher MA, Sikes RD Jr, Metchock B, Shinnick TM, Posey JE.

Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):20004-9. doi: 10.1073/pnas.0907925106. Epub 2009 Nov 11.

21.

Monitoring the performance of mycobacteriology laboratories: a proposal for standardized indicators.

McCarthy KD, Metchock B, Kanphukiew A, Monkongdee P, Sinthuwattanawibool C, Tasaneeyapan T, Rienthong S, Ngamlert K, Srisuwanvilai LO, Varma JK.

Int J Tuberc Lung Dis. 2008 Sep;12(9):1015-20.

PMID:
18713498
22.

Worldwide emergence of extensively drug-resistant tuberculosis.

Shah NS, Wright A, Bai GH, Barrera L, Boulahbal F, Martín-Casabona N, Drobniewski F, Gilpin C, Havelková M, Lepe R, Lumb R, Metchock B, Portaels F, Rodrigues MF, Rüsch-Gerdes S, Van Deun A, Vincent V, Laserson K, Wells C, Cegielski JP.

Emerg Infect Dis. 2007 Mar;13(3):380-7.

23.

Transmission network analysis to complement routine tuberculosis contact investigations.

Andre M, Ijaz K, Tillinghast JD, Krebs VE, Diem LA, Metchock B, Crisp T, McElroy PD.

Am J Public Health. 2007 Mar;97(3):470-7. Epub 2006 Oct 3.

24.

Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States.

Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A; Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC).

MMWR Recomm Rep. 2005 Dec 16;54(RR-15):49-55. Erratum in: MMWR Morb Mortal Wkly Rep. 2005 Dec 23;54(50):1288.

25.

Multidrug-resistant tuberculosis detection, Latvia.

Skenders G, Fry AM, Prokopovica I, Greckoseja S, Broka L, Metchock B, Holtz TH, Wells CD, Leimane V.

Emerg Infect Dis. 2005 Sep;11(9):1461-3.

26.

Mycobacterium tuberculosis transmission from human to canine.

Erwin PC, Bemis DA, McCombs SB, Sheeler LL, Himelright IM, Halford SK, Diem L, Metchock B, Jones TF, Schilling MG, Thomsen BV.

Emerg Infect Dis. 2004 Dec;10(12):2258-10. No abstract available.

27.

Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada.

Bozeman L, Burman W, Metchock B, Welch L, Weiner M; Tuberculosis Trials Consortium.

Clin Infect Dis. 2005 Feb 1;40(3):386-91. Epub 2005 Jan 7.

PMID:
15668861
28.

Recurrent tuberculosis in the United States and Canada: relapse or reinfection?

Jasmer RM, Bozeman L, Schwartzman K, Cave MD, Saukkonen JJ, Metchock B, Khan A, Burman WJ; Tuberculosis Trials Consortium.

Am J Respir Crit Care Med. 2004 Dec 15;170(12):1360-6. Epub 2004 Oct 11.

PMID:
15477492
29.

ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates.

Morlock GP, Metchock B, Sikes D, Crawford JT, Cooksey RC.

Antimicrob Agents Chemother. 2003 Dec;47(12):3799-805.

30.

Assessment of laboratory performance of nucleic acid amplification tests for detection of Mycobacterium tuberculosis.

Ridderhof JC, Williams LO, Legois S, Shult PA, Metchock B, Kubista LN, Handsfield JH, Fehd RJ, Robinson PH.

J Clin Microbiol. 2003 Nov;41(11):5258-61.

31.

Multicenter evaluation of ethambutol susceptibility testing of mycobacterium tuberculosis by agar proportion and radiometric methods.

Madison B, Robinson-Dunn B, George I, Gross W, Lipman H, Metchock B, Sloutsky A, Washabaugh G, Mazurek G, Ridderhof J.

J Clin Microbiol. 2002 Nov;40(11):3976-9.

32.

Multicenter evaluation of a nonweekend reading schedule for radiometric pyrazinamide susceptibility testing of Mycobacterium tuberculosis.

Madison B, Gross W, George I, Sloutsky A, Washabaugh G, Robinson-Dunn B, Lipman H, Metchock B, Mazurek G, Ridderhof J.

J Clin Microbiol. 2002 Oct;40(10):3753-6.

33.

Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial.

Benator D, Bhattacharya M, Bozeman L, Burman W, Cantazaro A, Chaisson R, Gordin F, Horsburgh CR, Horton J, Khan A, Lahart C, Metchock B, Pachucki C, Stanton L, Vernon A, Villarino ME, Wang YC, Weiner M, Weis S; Tuberculosis Trials Consortium.

Lancet. 2002 Aug 17;360(9332):528-34.

PMID:
12241657
34.

Comparison of methods for Identification of Mycobacterium abscessus and M. chelonae isolates.

Yakrus MA, Hernandez SM, Floyd MM, Sikes D, Butler WR, Metchock B.

J Clin Microbiol. 2001 Nov;39(11):4103-10.

35.

Mycobacterium kubicae sp. nov., a slowly growing, scotochromogenic Mycobacterium.

Floyd MM, Gross WM, Bonato DA, Silcox VA, Smithwick RW, Metchock B, Crawford JT, Butler WR.

Int J Syst Evol Microbiol. 2000 Sep;50 Pt 5:1811-6.

PMID:
11034491
36.

Clinical and programmatic mismanagement rather than community outbreak as the cause of chronic, drug-resistant tuberculosis in Buenaventura, Colombia, 1998.

Laserson KF, Osorio L, Sheppard JD, Hernández H, Benitez AM, Brim S, Woodley CL, Hazbón MH, Villegas MV, Castaño MC, Henriquez N, Rodriguez E, Metchock B, Binkin NJ.

Int J Tuberc Lung Dis. 2000 Jul;4(7):673-83.

PMID:
10907771
37.

Tuberculosis in the inner city: impact of a continuing epidemic in the 1990s.

Sotir MJ, Parrott P, Metchock B, Bock NN, McGowan JE Jr, Ray SM, Miller LP, Blumberg HM.

Clin Infect Dis. 1999 Nov;29(5):1138-44.

PMID:
10524954
38.

Evolution of extended-spectrum beta-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia.

Rasheed JK, Jay C, Metchock B, Berkowitz F, Weigel L, Crellin J, Steward C, Hill B, Medeiros AA, Tenover FC.

Antimicrob Agents Chemother. 1997 Mar;41(3):647-53.

39.

Childhood mortality during and after hospitalization in western Kenya: effect of malaria treatment regimens.

Zucker JR, Lackritz EM, Ruebush TK 2nd, Hightower AW, Adungosi JE, Were JB, Metchock B, Patrick E, Campbell CC.

Am J Trop Med Hyg. 1996 Dec;55(6):655-60. Erratum in: Am J Trop Med Hyg 1997 Mar;56(3):358.

PMID:
9025694
41.

Basic microbiologic support for hospital epidemiology.

McGowan JE Jr, Metchock BG.

Infect Control Hosp Epidemiol. 1996 May;17(5):298-303. Review.

PMID:
8727619
42.
43.

Detection of penicillin-resistant Streptococcus pneumoniae with commercially available broth microdilution panels.

Nolte FS, Metchock B, Williams T, Diem L, Bressler A, Tenover FC.

J Clin Microbiol. 1995 Jul;33(7):1804-6.

44.

Penicillin-resistant pneumococci--an emerging threat to successful therapy.

McGowan JE Jr, Metchock BG.

J Hosp Infect. 1995 Jun;30 Suppl:472-82.

PMID:
7560986
45.

Laboratory diagnosis of tuberculosis: past, present, and future.

McGowan JE Jr, Metchock B, Nolte FS.

J Med Assoc Ga. 1995 May;84(5):215-20. Review.

PMID:
7782707
46.

Evaluation of travelers returning from the 1992 Olympics in Barcelona, Spain: did they acquire resistant pneumococci and meningococci?

Stienecker RS, Steinberg JP, Schwartz B, Metchock B, Kozarsky PE.

Clin Infect Dis. 1995 Mar;20(3):731-2. No abstract available.

PMID:
7756515
47.

Third generation cephalosporin-resistant gram-negative bacilli in the feces of hospitalized children.

Berkowitz FE, Metchock B.

Pediatr Infect Dis J. 1995 Feb;14(2):97-100.

PMID:
7746715
48.

Severe illness in African children with diarrhoea: implications for case management strategies.

Lee LA, Dogore R, Redd SC, Dogore E, Metchock B, Diabate J, van Assendelft OW, DeCock K, Patrick E, Herrington J.

Bull World Health Organ. 1995;73(6):779-85.

49.

Predictors of survival in patients with AIDS and disseminated Mycobacterium avium complex disease.

Horsburgh CR Jr, Metchock B, Gordon SM, Havlik JA Jr, McGowan JE Jr, Thompson SE 3rd.

J Infect Dis. 1994 Sep;170(3):573-7.

PMID:
8077714
50.

Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease.

Gordon SM, Horsburgh CR Jr, Peloquin CA, Havlik JA Jr, Metchock B, Heifets L, McGowan JE Jr, Thompson SE 3rd.

J Infect Dis. 1993 Dec;168(6):1559-62.

PMID:
8245546

Supplemental Content

Loading ...
Support Center